Vol. XXXI, n.1, 2010 ISSN: 0392-2936


european journal
of gynaecological oncology

an International Journal


Founding Editor
A. Onnis
Montréal (Canada)

Editors-in-Chief
M. Marchetti
Montréal (Canada)
P. Bösze
Budapest (Hungary)

Associate Editor
T. Maggino
Padua (Italy)

Assistant Editor
J. Wilson
San Diego - CA (USA)
Editorial Board
Allen H.H., London, Ontario (Canada)
Anteby S.O., Jerusalem (Israel)
Audet-Lapointe P., Montreal (Canada)
Ayhan A., Ankara (Turkey)
Balat O., Graziantep (Turkey)
Ba˘nceanu G., Bucarest (Romania)
Basta A., Krakow (Poland)
Bender H.C., Dusseldorf (Germany)
Benedetti Panici P.L., Rome (Italy)
Charkviani T., Tbilisi (Georgia)
De Oliveira C.F., Coimbra (Portugal)
Dexeus S. Jr., Barcelona (Spain)
Di Paola G.R.,
Buenos Aires (Argentina)
Di Re F., Milan (Italy)
Di Saia P., Orange, CA (USA)
Friedrich M., Hamburg (Germany)
Fuller A.F. Jr., Boston, MA (USA)
Geisler H.E., Indianapolis, IN (USA)
Gerbaulet A., Villejuif (France)
Gorins A., Paris (France)
Heintz A.P.M.,
Utrecht (The Netherlands)
Ioannidou-Mouzaka L.,
Athens (Greece)
Jordan J.A.,
Birmingham, England (UK)
Karseladze A.I., Moscow (Russia)
Klastersky J., Bruxelles (Belgium)
Kubista E., Vienna (Austria)
Maggino T., Padua (Italy)
Markowska J., Poznan (Poland)
Marth C., Innsbruck (Austria)
Massuger Leon F.A.G.,
Nijmegen (The Netherlands)
Menczer J., Savyon (Israel)
Monsonego J., Paris (France)
Pálfalvi L., Budapest, (Hungary)
Pinotti A., São Paulo (Brazil)
Piura B., Beer Sheva (Israel)
Piver S.M., Buffalo, NY (USA)
Rakar S., Ljubljana (Slovenia)
Raju K.S., London, England (UK)
Shepherd J.H.,
London, England (UK)
Stelmachów J., Warsaw (Poland)
Tjalma W., Antwerpen (Belgium)
Ungár L., Budapest (Hungary)
Vermorken J.B., Edegem (Belgium)
Wang P.-H., Taipei (Taiwan)
Winter R., Graz (Austria)
Yokoyama Y., Hirosaki (Japan)

Publishing Organization (M. Morsani):
I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc - Apt # 212 - Montréal, Qué. H3W 2H3 (Canada)
Tel. +514-4893242 - Fax +514-4854513 - E-mail: canlux@mgroup-online.com - www.irog.net

Editorial Office (M. Critelli):
Galleria Storione, 2/A - 35123 Padua (Italy) - Tel. (39) 049 8756900 - Fax (39) 049 8752018

 

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed works in the fields of female genital cancers and related subjects and also proceedings of gynecologic oncology society meetings all over the world. The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/ Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

 

European Journal of Gynaecological Oncology
www.irog.net


General Information

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed work, preferably brief reports, in the fields of female genital cancers and related subjects – prevention, early detection, epidemiology, pathology, diagnosis, management – and also proceedings of Gynaecologic Oncology Society meetings all over the world.

The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE,
EMBASE/ Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

AIMS AND SCOPE
The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing editorial articles in the “Distin-guished Expert Series” and original research papers, case reports, letters to the Editor, book reviews and newsletters.

The Journal was founded in 1980 – the second gynaecologic oncology hyperspecialization journal in the world. Its aim is the dif-fusion of scientific, clinical and practical progress and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists and so on.

ANNOUNCEMENTS regarding meetings, postgraduate courses and symposia will be accepted 6 months before publication and will be published free of charge.
BOOK SAMPLES for review should be sent to the Editorial offices in Montréal or in Padova.
COPYRIGHT: the Journal has been registered with the Copyright Clearance Center, Inc. Reproductions are not allowed without the written consent of the Publisher. All photocopy fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating the ISSN number, the volume and the first and last page numbers of each article copied.
ADVERTISING INFORMATION: advertising orders and inquiries may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc, Apt. 212, Montréal (Quebec) Canada H3W 2HS, Tél. 514.4893242-4893640 - Fax 514.4854513 - E-mail: canlux@mgroup-online.com - www.irog.net
RESPONSIBILITY: although every effort is made by the editorial staff and the printer to eliminate misleading or inaccurate infor-mation, the publisher accepts no responsibility for the consequences of faultful or incorrect information. The authors recognize that the editor and publisher have no responsibility and are indemnified against any liability or claim that may result from the publication of misleading or incorrect data.


SUBSCRIPTION INFORMATION
The Journal is published bimonthly (January, March, May, July, September and November); one volume per year. Subscriptions start from January and are automatically renewed if not cancelled by the end of September.

Subscriptions include six issues per year plus supplements, monographs and all official communications of Meetings, Courses, Symposia and all scientific activities of Gynaecologic Oncology Societies all over the world.

Subscriptions are entered with prepayment only. The annual subscription is $390 US for Institutions, $200 US for Individuals. For airmail add $30, for receipt add $10 US. Single copy prepaid cost $95 US.

Send subscription requests with cheque or credit card payment (Amex - Visa - Diner’s - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. Only US Funds are accepted. No bank transfers.

Claims for missing issues can be honoured up to six months. Changes of address: allow six weeks for all changes to become effec-tive. All communications should include both old and new addresses (with postal codes) – better if accompanied by a mailing label from a recent issue – and should be sent to the printer: La Garangola, Via E. Dalla Costa 6, 35129 Padova (Italy) or by Fax +39.049.7806580. Claims should be made within six months of publication date.

Duplicate copies will not be sent to replace those undelivered through failure to notify of change of address.

Single copies and back issue and volume information is available from the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580. Certain back issues may only be available as photocopies of the originals.

All other business correspondence including orders for offprints and advertising space and any communication and requests should be addressed to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.

IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT

 

European Journal of Gynaecological Oncology
www.irog.net


Instructions to Authors

SUBMISSION OF MANUSCRIPTS
Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212 MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513, or Galleria Sto-rione 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.

Editorial articles for publication in the “Distinguished Expert Series” should be submitted to P. Bösze, Editor-in-Chief of this section, Department of Gynecology, Saint Stephan Hospital, 1096 Budapest, Nagyvárad tér 1, Telephone (36-1) 275 2172, Fax (36-1)
275 2172, E-mail: bosze@axelero.hu

When a manuscript is submitted, an acknowledgement card is sent to the corresponding author within two or three weeks.

Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees. Authors may be required to modify the manuscript according to the reviewers’ suggestions.

Manuscripts accepted for publication will be copyedited by the editorial staff for typographical and grammatical mistakes and to guarantee clarity and conciseness.

Publication time will be the shortest possible based on scientific and publishing needs. Manuscripts submitted for publi-cation cannot be returned.

Published papers will become property of the Journal and copyrighted under I.R.O.G. CANADA Inc.

After six months no grievances will be accepted regarding published articles.

All statements are the responsibility of the authors. Product dosages, indications and methods referred to in the papers reflect the author’s experience. No responsibility is assumed by the Editor-in-Chief or the Publisher for any damage from use of any products, operation methods or instructions contained in the published materials.

Trade names, trademarks, etc. are protected by the law and regulations. The Editor-in-Chief and the Publisher cannot accept any legal responsibility for any errors or omissions that may be made in press, particularly for information about drug dosage and appli-cation thereof contained in the Journal. Consult the prescribing information before administering any drug.

MANUSCRIPT REQUIREMENTS
The Journal follows the “Uniform requirements for manuscripts submitted to biomedical journals” published in the New England Journal of Medicine 1991, 324, 424-8 and in the British Medical Journal 1991, 302.

Three manuscripts, typed and double spaced should be submitted with an electronic disk, formatted in Word for Macintosh or Windows, version 6.0. Manuscripts without an electronic disk will not be accepted. A cover letter signed by all authors must state that all authors who have participated in the work take responsibility for the manuscript which has never been pub lished or submitted for publication elsewhere. Without a cover letter the publication will not be possible. Name, address and phone/fax numbers of the Corresponding Author, responsible for revision and approval of the proofs, should be indicated. Full-length articles should not exceed 8 printed pages including tables and references.

After the title page (full title and names of authors, institutions, eventual acknowledgement for financial support, running title of no more than 60 characters or spaces), original works should be arranged in the conventional order: Summary (purpose of investiga-tion, methods, results, conclusion - about 150 words), Key words, Content (a 20-word summary), Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgement (if any), References, Tables, Legends.

Authors should supply a complete address for reprint requests.

In the text only standard abbreviations can be used and must be avoided in the title. The full term for which an abbreviation stands should precede its first use in the summary and text unless it is a standard unit of measurement.

Authors must give their complete professional identifications and affiliations, including all academic titles and positions.

Letters to the editor should be brief (500 words or less) and offer objective, constructive and educational criticism of published material. The editor reserves the right to publish.

Figures: Two original copies (not negatives) of each figure are requested. Each figure should have a label on the back indicating its number, author’s name and top of the figure. Do not write on the back of the figures and do not mount them on cardboard. If sending colour pictures advise if they must be printed in colour or black and white (colour costs ten times more).

Legends should be typed on a separate page with Arabic numerals corresponding to the illustrations.

Tables should be titled, typed in double space on separate pages and numbered in Arabic numerals in the order of their first cita-tion
in the text. Do not use internal rules. Only standard, universally understood abbreviations should be used.

References should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in the text, tables, and legends by Arabic numerals in parentheses.

Use the style of the examples below, which are based with slight modifications on the format used by the U.S. National Library of Medicine in Index Medicus. The titles of journals should be abbreviated according to the style used in Index Medicus.

References must be verified by the Author(s) against the original documents.

Examples of correct forms of references are given below:

Articles in Journals: Authors’ surname and initials (if more than six names, give six followed by “et al.”), Title, Abbreviated Journal Title, Year of Publication, Volume, Issue and first page.

Books: Authors’ surname and initials, title of the book and title of chapter, in: Title, Editor(s), Place, Publisher, Year, Page.

Acknowledgments
will be limited to appropriate professionals who were contributors to the paper.

PROOFS revised by the editorial staff will be sent to the corresponding author and should be checked and returned within ten days. The corresponding author is responsible for detecting typesetting errors. After this deadline the proofs will be considered approved. Only essential corrections should be made; extensive changes will be charged to the authors.

BUSINESS MATTERS
The Journal has no commercial advertisements.

Authors will be expected to contribute to the printing expenses, tables, figures and postage. For every published article a copy of the Journal will be provided free of charge. Only payments in US dollars will be accepted. No bank transfers.

Reprints should be requested with the form enclosed with the acceptance letter. No free reprints will be supplied.



© By I.R.O.G. CANADA INC. - Publisher - Editorial office 4900 Côte St. Luc - Apt. 212 - Montréal Québec H3W 2H3 (Canada) - Tel. (514) 4893242-4893640 - Fax (514) 4854513 - Printed in Italy by “La Garangola” - Via E. Dalla Costa, 6 - 35129 Padua (Italy) - Responsible Director: Prof. Antonio Onnis M.D. - Authorization of Padua’s Court n. 633 - 28-6-1979
ORIGINAL ARTICLES  
Referral and ascertainment bias in patients with synchronous and metachronous endometrial malignancy 5
A. Mariani, S.S. Cha, E.J. Bergstralh, L.A. Boardman, S.C. Dowdy, G.L. Keeney, K.C. Podratz, L.J. Melton III - Rochester, MN (USA)
Endometrial cancer patients may develop other associated malignancies; study results from tertiary care centers may be misleading because of referral biases.
 
Impact of three-dimensional (3D) ultrasonography and power Doppler angiography in the management of cervical cancer 10
K. Tanaka, N. Umesaki - Wakayama-shi, JAPAN
Three-dimensional power Doppler ultrasound may be useful to monitor the response to treatment in a patient with cervical cancer.
 
Out-of-protocol concurrent use of cisplatin and radiation therapy in locally advanced cervical cancer: feasibility and survival 18
G. Mancebo, A. Gil-Moreno, R. Vergés, J.M. Martínez-Palones, M.A. Checa, J.M.R. Carreras, J. Giralt, J. Xercavins - Barcelona, SPAIN
Out-of-protocol concurrent use of cisplatin-based chemotherapy and radiation therapy is feasible and effective in locally advanced cervical cancer.
 
Shoulder mobility after axillary sentinel node biopsy for early infiltrating breast cancer treatment 23
K.U. Favarão, J.C. Mantese, A.C.S.D. Barros - São Paulo, BRAZIL
Shoulder mobility restriction in sentinel node biopsy is transitory, lasting up to three months, and should be relieved by early physiotherapeutic interventions.
 
The significance of HPV in the follow-up period after treatment for CIN 27
J. Gallwas, N. Ditsch, P. Hillemanns, K. Friese, C. Thaler, C. Dannecker - Munich, GERMANY
HPV testing showed a sensitivity of 93% in CIN recurrence and therefore should be integrated in a follow-up algorithm.
 
Possible role of palliative surgery for bowel obstruction in advanced ovarian cancer patients 31
E. Sartori, F. Chiudinelli, B. Pasinetti, B. Sostegni, T. Maggino - Venice-Mestre, ITALY
Bowel obstruction is a relatively common event in the late natural history of advanced and recurrent ovarian cancer patients. Risk score analysis may identify a subgroup of patients suitable for surgical treatment.
 
The incidence, treatment and prognosis of cervical carcinoma in young women: a retrospective analysis of 4,975 cases in Japan 37

K. Kokawa, S. Takekida, S. Kamiura, M. Kita, T. Enomoto, R. Kawaguchi, J. Saito, A. Horie, N. Umesaki - Kyoto, JAPAN
The incidence of cervical carcinoma in young women was increased but the prognosis was better when compared with all patients.

 
Prediction of suboptimal cytoreduction of epithelial ovarian carcinoma by preoperative computed tomography 44
M. Kebapci, A.K. Akca, O.T. Yalcin, S.S. Ozalp, C. Calisir, F. Mutlu - Eskisehir, TURKEY
Suboptimal surgery in patients with epithelial ovarian cancer could be predicted by preoperative CT
 
Analysis of odds ratio of increased relative risk of developing breast cancer in different groups of women 50
B. Pieta, D. Samulak, T. Opala, M. Wilczak, S. Grodecka-Gazdecka, K. Wie ˛znowska-Ma ˛czyn ´ska - Poznan
POLAND
Quantitive assessment of risk of developing breast carcinoma enables identification of women with increased risk and the
choice of the proper diagnosis.
 
Analysis of protein profiles in human epithelial ovarian cancer tissues by proteomic technology 55
S.N. Chow, R.J. Chen, C.H. Chen, T.C. Chang, L.C. Chen, W.J. Lee, J. Shen, L.P. Chow - Taipei, TAIWAN
The present study is the first to report the down-regulation of SH3 binding glutamate-rich protein and tubulin-specific chaper- one A in human ovarian cancer tissues.
 
Mesothelin gene expression and promoter methylation/hypomethylation in gynecological tumors 63
G. Obulhasim, H. Fujii, T. Matsumoto, M. Yasen, M. Abe, S. Matsuoka, N. Ohtsuji, O. Hino - Xinjiang, CHINA
Mesothelin expression in gynecological tumors may be influenced by the methylation/hypomethylation status at CpG sites in its promoter.
 
Prevalence of human papilloma virus infection in pregnant Turkish women compared with non-pregnant women 72
Y. Aydin, A. Atis, T. Tutuman, N. Goker - Istanbul, TURKEY
Prevalence of HPV viruses is higher in pregnant Turkish women versus non-pregnant women - especially the high-risk genotypes for cervical cancer
 
Analysis of the cytogenetic response in peripheral blood lymphocytes from breast cancer patients following chemotherapy 75
P.A. Resende, C. Fidalgo, P.M. Alves, B.M. Tavares-Murta, E.F.C. Murta, F.L. Dias - Uberaba, MG (BRAZIL)
Chemotherapy raises the number of chromosomal aberrations in women with breast cancer and favors persistence of these abnormalities.
 
Is sentinel node biopsy reliable in large breast tumors? 80
D. Koukouras, C. Spyropoulos, N. Siasos, E. Sdralis, E. Tzorakoleftherakis - Patras, GREECE
Larger breast tumors seem to be associated with increased incidence of nodal metastases while multifocality appears to be related to increased false-negative rates of sentinel node detection.
 
Laser vaporization in the management of CIN 83
G. Vetrano, P. Ciolli, S. Carboni, P. Scardamaglia, V. Aleandri, M. Verrico, R. Corosu - Rome, ITALY
The effectiveness of CO2 laser vaporization and diagnostic reliability of cytology, colposcopy, microbiology and HPV testing in patients affected by HG-CIN was evaluated.
 
Sonographic value in diagnosis of hemorrhagic ovarian cysts 87
Z. Ding, D. Zhang, W. Ying, J. Wang - Hangzhou, CHINA
Sonographic characteristics of hemorrhagic ovarian cysts (HOC) were investigated, and sonographic and clinical follow-up conducted.
 
E-cadherin expression in estrogen receptor-positive and negative breast carcinomas of postmenopausal women 90
B.B. da Silva, A.R. dos Santos, C.G. Pires, M.A. Correa-Lima, J.D.D. Pereira-Filho, L.G. dos Santos, C.S. Moura, P.V. Lopes-Costa - Piauí, BRAZIL
E-cadherin expression loss is significantly associated with ER-negative tumors and therefore with a more aggressive phenotype of invasive ductal breast carcinoma.
 
Granulosa cell tumors of the ovary: a clinicopathologic and immunohistochemical study of 21 cases 94
A. Kondi-Pafiti, D. Grapsa, E. Kairi-Vassilatou, E. Carvounis, D. Hasiakos, K. Kontogianni, S. Fotiou - Athens, GREECE
The clinicopathologic and immunohistochemical features of 21 cases of adult and juvenile granulosa cell tumors of the ovary are presented.
 
Uterine involvement in advanced epithelial ovarian cancer 99
N. Behtash, M. Karimi Zarchi, T. Ashraf-Ganjoei - Kerman, IRAN
A retrospective study of the involvement of uterine tissues in ovarian cancer is reported.
 
 
CASE REPORTS  
Primary non-Hodgkins lymphoma of the ovary in the background of human immunodeficiency virus (HIV): A bold and curative approach to treatment 102
P.S. Govender, M. Moodley - Durban, SOUTH AFRICA
The presentation and management of a rare case of HIV-associated primary non-Hodgkins lymphoma of the ovary are discussed
 
High levels of xenoestrogens in patients with low-grade endometrial stromal sarcoma - report of two cases 105
O. Reich, S. Regauer, S. Scharf - Vienna, AUSTRIA
Increased levels of xenoestrogens may be involved in the pathogenesis of endometrial stromal sarcoma.
 
Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature 107
K.R. Brown, M.M. Leitao Jr. - New York, NY (USA)
A case of a patient with neuroendocrine tumor of the cervix who developed lethargy, dizziness, confusion, and severe hyponatremia consistent with the syndrome of inappropriate antidiuretic hormone three days after administration of cisplatin is described.
 
Choroidal melanoma metastasized to the ovary: case report and review of the literature 109
V.D. Mandato, B. Kobal, A. Di Stefano, J. Sinkovec, A. Levicnik, G.B. La Sala, S. Rakar - Ljubljana, SLOVENIA
A rare case of choroidal melanoma metastasized to the ovary is reported.
 
Muscle metastasis of low-grade endometrial carcinoma seven years after diagnosis: A case report 114
A. Oaknin, M.P. Barretina, I. Morilla - Barcelona, SPAIN
Unusual behaviour of low-grade endometrial carcinoma is presented. The patient presented with muscle metastases seven years after diagnosis.
 
Pure Sertoli cell tumor. A case report and review of the literature 117
A. Zizi-Sermpetzoglou, N. Petrakopoulou, N. Tepelenis, V. Savvaidou, K. Manoloudaki, M. Katsoulis - Pireaus, GREECE
A case of a sex-cord tumor of the ovary with the typical macroscopic and microscopic features of a pure Sertoli-cell tumor is presented.
 
Immunohistochemical findings in primary fallopian tube cancer. Case report 120
G. Raba, P. Laudanski, L. Kanczuga-Koda - Bialystok, POLAND
It has been clearly shown that immunohistochemical expression of ER-β is dominant over ER-α in primary fallopian tube cancer.
 
Good prognosis for primary ovarian pure nongestational choriocarcinoma using the EMA/CO regime 123
E. Ozturk, M. Gurol Ugur, F. Bahar Cebesoy, A. Aydın, T. Sever, O. Balat - Gaziantep, TURKEY
The clinical features, management and outcome of nongestational choriocarcinoma treated by the EMA/CO protocol are discussed.
 
Primary malignant mixed müllerian tumour of the fallopian tube. Report of a case 126
E. Skafida, X. Grammatoglou, E. Katsamagkou, Ch. Glava, N. Firfiris, Th. Vasilakaki - Larissa, GREECE
A case of a 60-year-old woman with primary malignant mixed müllerian tumour of the fallopian tube is presented.
 
   
ERRATA - CORRIGE 711
   

Primary clear cell carcinoma of the peritoneum: report of two cases and a review of the literature
Vol. XXX, n. 5, 2009, page 575


Errata:
M. Takano, T. Yoshokawa, M. Kato, S. Aida, T. Goto, K. Furuya, Y. Kikuchi
Corrige:
M. Takano, T. Yoshikawa, M. Kato, S. Aida, T. Goto, K. Furuya, Y. Kikuchi

720